A citation-based method for searching scientific literature

Antonio C Wolff, M Elizabeth Hale Hammond, Kimberly H Allison, Brittany E Harvey, Pamela B Mangu, John M S Bartlett, Michael Bilous, Ian O Ellis, Patrick Fitzgibbons, Wedad Hanna, Robert B Jenkins, Michael F Press, Patricia A Spears, Gail H Vance, Giuseppe Viale, Lisa M McShane, Mitchell Dowsett. J Clin Oncol 2018
Times Cited: 492







List of co-cited articles
446 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C Wolff, M Elizabeth H Hammond, David G Hicks, Mitch Dowsett, Lisa M McShane, Kimberly H Allison, Donald C Allred, John M S Bartlett, Michael Bilous, Patrick Fitzgibbons,[...]. J Clin Oncol 2013
24

Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
Kimberly H Allison, M Elizabeth H Hammond, Mitchell Dowsett, Shannon E McKernin, Lisa A Carey, Patrick L Fitzgibbons, Daniel F Hayes, Sunil R Lakhani, Mariana Chavez-MacGregor, Jane Perlmutter,[...]. J Clin Oncol 2020
171
24

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, Mitch Dowsett, D Craig Allred, Karen L Hagerty, Sunil Badve, Patrick L Fitzgibbons, Glenn Francis, Neil S Goldstein, Malcolm Hayes,[...]. J Clin Oncol 2010
16

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C Wolff, M Elizabeth H Hammond, Jared N Schwartz, Karen L Hagerty, D Craig Allred, Richard J Cote, Mitchell Dowsett, Patrick L Fitzgibbons, Wedad M Hanna, Amy Langer,[...]. J Clin Oncol 2007
10

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa,[...]. Lancet 2014
10

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D J Slamon, G M Clark, S G Wong, W J Levin, A Ullrich, W L McGuire. Science 1987
9



Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde, T Fleming, W Eiermann, J Wolter, M Pegram,[...]. N Engl J Med 2001
8

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Shanu Modi, Haeseong Park, Rashmi K Murthy, Hiroji Iwata, Kenji Tamura, Junji Tsurutani, Alvaro Moreno-Aspitia, Toshihiko Doi, Yasuaki Sagara, Charles Redfern,[...]. J Clin Oncol 2020
98
7

Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, Maggie C U Cheang, Samuel Leung, David Voduc, Tammi Vickery, Sherri Davies, Christiane Fauron, Xiaping He, Zhiyuan Hu,[...]. J Clin Oncol 2009
7

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, Jens-Uwe Blohmer, Serban D Costa, Holger Eidtmann, Peter A Fasching, Bernd Gerber, Wolfgang Eiermann, Jörn Hilfrich, Jens Huober,[...]. J Clin Oncol 2012
7

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.
H J Burstein, G Curigliano, S Loibl, P Dubsky, M Gnant, P Poortmans, M Colleoni, C Denkert, M Piccart-Gebhart, M Regan,[...]. Ann Oncol 2019
224
7

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
7

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.
Wedad M Hanna, Josef Rüschoff, Michael Bilous, Renata A Coudry, Mitch Dowsett, Robert Y Osamura, Frédérique Penault-Llorca, Marc van de Vijver, Giuseppe Viale. Mod Pathol 2014
179
6


Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
W Fraser Symmans, Florentia Peintinger, Christos Hatzis, Radhika Rajan, Henry Kuerer, Vicente Valero, Lina Assad, Anna Poniecka, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2007
791
6

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, Della F Makower, Kathleen I Pritchard, Kathy S Albain, Daniel F Hayes, Charles E Geyer, Elizabeth C Dees, Matthew P Goetz, John A Olson,[...]. N Engl J Med 2018
793
6

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.
Mitch Dowsett, Torsten O Nielsen, Roger A'Hern, John Bartlett, R Charles Coombes, Jack Cuzick, Matthew Ellis, N Lynn Henry, Judith C Hugh, Tracy Lively,[...]. J Natl Cancer Inst 2011
6

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh,[...]. Lancet 2010
6



Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
A S Coates, E P Winer, A Goldhirsch, R D Gelber, M Gnant, M Piccart-Gebhart, B Thürlimann, H-J Senn. Ann Oncol 2015
972
6

HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.
Yanjun Hou, Hiroaki Nitta, Lai Wei, Peter M Banks, Bryce Portier, Anil V Parwani, Zaibo Li. Breast Cancer Res Treat 2017
35
14

'Non-classical' HER2 FISH results in breast cancer: a multi-institutional study.
Morgan Ballard, Florencia Jalikis, Gregor Krings, Rodney A Schmidt, Yunn-Yi Chen, Mara H Rendi, Suzanne M Dintzis, Kristin C Jensen, Robert B West, Richard K Sibley,[...]. Mod Pathol 2017
46
10

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
Gunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, Sibylle Loibl, Eleftherios P Mamounas, Michael Untch, Norman Wolmark, Priya Rastogi, Andreas Schneeweiss, Andres Redondo,[...]. N Engl J Med 2019
625
5

HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.
Michael F Press, Guido Sauter, Marc Buyse, Hélène Fourmanoir, Emmanuel Quinaux, Denice D Tsao-Wei, Wolfgang Eiermann, Nicholas Robert, Tadeusz Pienkowski, John Crown,[...]. J Clin Oncol 2016
83
6

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
C Davies, J Godwin, R Gray, M Clarke, D Cutter, S Darby, P McGale, H C Pan, C Taylor, Y C Wang,[...]. Lancet 2011
5

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Brian D Lehmann, Joshua A Bauer, Xi Chen, Melinda E Sanders, A Bapsi Chakravarthy, Yu Shyr, Jennifer A Pietenpol. J Clin Invest 2011
5

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
Brett Wallden, James Storhoff, Torsten Nielsen, Naeem Dowidar, Carl Schaper, Sean Ferree, Shuzhen Liu, Samuel Leung, Gary Geiss, Jacqueline Snider,[...]. BMC Med Genomics 2015
210
5

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
Jeffrey S Ross, Elzbieta A Slodkowska, W Fraser Symmans, Lajos Pusztai, Peter M Ravdin, Gabriel N Hortobagyi. Oncologist 2009
734
5

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Edward H Romond, Edith A Perez, John Bryant, Vera J Suman, Charles E Geyer, Nancy E Davidson, Elizabeth Tan-Chiu, Silvana Martino, Soonmyung Paik, Peter A Kaufman,[...]. N Engl J Med 2005
5

Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay.
Dara S Ross, Ahmet Zehir, Donavan T Cheng, Ryma Benayed, Khedoudja Nafa, Jaclyn F Hechtman, Yelena Y Janjigian, Britta Weigelt, Pedram Razavi, David M Hyman,[...]. J Mol Diagn 2017
50
10

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Martine J Piccart-Gebhart, Marion Procter, Brian Leyland-Jones, Aron Goldhirsch, Michael Untch, Ian Smith, Luca Gianni, Jose Baselga, Richard Bell, Christian Jackisch,[...]. N Engl J Med 2005
5

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, R Tibshirani, T Aas, S Geisler, H Johnsen, T Hastie, M B Eisen, M van de Rijn, S S Jeffrey,[...]. Proc Natl Acad Sci U S A 2001
5

Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.
Kimberly H Allison, M Elizabeth H Hammond, Mitchell Dowsett, Shannon E McKernin, Lisa A Carey, Patrick L Fitzgibbons, Daniel F Hayes, Sunil R Lakhani, Mariana Chavez-MacGregor, Jane Perlmutter,[...]. Arch Pathol Lab Med 2020
61
8

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
5


Prognostic and predictive factors in breast cancer by immunohistochemical analysis.
D C Allred, J M Harvey, M Berardo, G M Clark. Mod Pathol 1998
5

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.
Louis Fehrenbacher, Reena S Cecchini, Charles E Geyer, Priya Rastogi, Joseph P Costantino, James N Atkins, John P Crown, Jonathan Polikoff, Jean-Francois Boileau, Louise Provencher,[...]. J Clin Oncol 2020
55
9

Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance.
Hyesil Seol, Hyun Ju Lee, Yoomi Choi, Hee Eun Lee, Yu Jung Kim, Jee Hyun Kim, Eunyoung Kang, Sung-Won Kim, So Yeon Park. Mod Pathol 2012
188
4

HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.
Hee Jin Lee, An Na Seo, Eun Joo Kim, Min Hye Jang, Koung Jin Suh, Han Suk Ryu, Yu Jung Kim, Jee Hyun Kim, Seock-Ah Im, Gyungyub Gong,[...]. Am J Clin Pathol 2014
71
5

Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.
Wedad Hanna, Sharon Nofech-Mozes, Harriette J Kahn. Breast J 2007
72
5

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
Ethan Cerami, Jianjiong Gao, Ugur Dogrusoz, Benjamin E Gross, Selcuk Onur Sumer, Bülent Arman Aksoy, Anders Jacobsen, Caitlin J Byrne, Michael L Heuer, Erik Larsson,[...]. Cancer Discov 2012
4

Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study.
C A Purdie, P Quinlan, L B Jordan, A Ashfield, S Ogston, J A Dewar, A M Thompson. Br J Cancer 2014
96
4

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, Gong Tang, Chungyeul Kim, Joffre Baker, Maureen Cronin, Frederick L Baehner, Michael G Walker, Drew Watson, Taesung Park,[...]. N Engl J Med 2004
4

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
W Fraser Symmans, Caimiao Wei, Rebekah Gould, Xian Yu, Ya Zhang, Mei Liu, Andrew Walls, Alex Bousamra, Maheshwari Ramineni, Bruno Sinn,[...]. J Clin Oncol 2017
241
4

A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, Laura J van't Veer, Hongyue Dai, Augustinus A M Hart, Dorien W Voskuil, George J Schreiber, Johannes L Peterse, Chris Roberts, Matthew J Marton,[...]. N Engl J Med 2002
4

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
Amanda N Fader, Dana M Roque, Eric Siegel, Natalia Buza, Pei Hui, Osama Abdelghany, Setsuko K Chambers, Angeles Alvarez Secord, Laura Havrilesky, David M O'Malley,[...]. J Clin Oncol 2018
137
4

HER2-positive breast cancer.
Sibylle Loibl, Luca Gianni. Lancet 2017
282
4


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.